Journal
VACCINE
Volume 37, Issue 38, Pages 5762-5769Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2018.09.037
Keywords
Vaccine; Vaccine carrier; Malaria; Host cell protein; Mass spectrometry; ExoProtein A; Purification; Mixed-mode chromatography
Categories
Funding
- Intramural Research Program of the National Institute for Allergy and Infectious Diseases, National Institutes of Health
- RTB
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZICAI001051] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Efforts to develop a vaccine for the elimination of malaria include the use of carrier proteins to assemble monomeric antigens into nanoparticles to maximize immunogenicity. Recombinant ExoProtein A (EPA) is a detoxified form of Pseudomonas aeruginosa Exotoxin A which has been used as a carrier in the conjugate vaccine field. A pilot-scale process developed for purification of EPA yielded product that consistently approached a preset upper limit for host cell protein (HCP) content per human dose. To minimize the risk of bulk material exceeding the specification, the purification process was redeveloped using mixed-mode chromatography resins. Purified EPA derived from the primary and redeveloped processes were comparable following full biochemical and biophysical characterization. However, using a process specific immunoassay, the HCP content was shown to decrease from a range of 0.14-0.24% w/w of total protein to below the level of detection with the revised process. The improved process reproducibly yields EPA with highly similar quality characteristics as the original process but with an improved profile for the HCP content. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available